JP2021507877A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021507877A5 JP2021507877A5 JP2020528402A JP2020528402A JP2021507877A5 JP 2021507877 A5 JP2021507877 A5 JP 2021507877A5 JP 2020528402 A JP2020528402 A JP 2020528402A JP 2020528402 A JP2020528402 A JP 2020528402A JP 2021507877 A5 JP2021507877 A5 JP 2021507877A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- antibody
- hvr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/114247 WO2019104716A1 (en) | 2017-12-01 | 2017-12-01 | Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody |
| CNPCT/CN2017/114247 | 2017-12-01 | ||
| PCT/CN2018/118631 WO2019105468A1 (en) | 2017-12-01 | 2018-11-30 | Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021507877A JP2021507877A (ja) | 2021-02-25 |
| JP2021507877A5 true JP2021507877A5 (enExample) | 2022-01-06 |
Family
ID=66664325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020528402A Pending JP2021507877A (ja) | 2017-12-01 | 2018-11-30 | Ｃｄ１３７リガンドを抗ｃｄ１３７抗体を用いた治療向けのバイオマーカーとして使用するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200377608A1 (enExample) |
| EP (1) | EP3717010A4 (enExample) |
| JP (1) | JP2021507877A (enExample) |
| CN (1) | CN111344014A (enExample) |
| AU (1) | AU2018377751A1 (enExample) |
| CA (1) | CA3079479A1 (enExample) |
| SG (1) | SG11202004939SA (enExample) |
| WO (2) | WO2019104716A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201907753TA (en) | 2017-02-24 | 2019-09-27 | Macrogenics Inc | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| TWI841551B (zh) * | 2018-03-13 | 2024-05-11 | 瑞士商赫孚孟拉羅股份公司 | 使用靶向4-1bb (cd137)之促效劑的組合療法 |
| WO2019197600A1 (en) * | 2018-04-13 | 2019-10-17 | F. Hoffmann-La Roche Ag | Her2-targeting antigen binding molecules comprising 4-1bbl |
| JP7598312B2 (ja) | 2018-07-23 | 2024-12-11 | ハイデルベルク ファーマ リサーチ ゲーエムベーハー | 同種異系の細胞療法における抗－ｃｄ１３７抗体薬物コンジュゲート（ａｄｃ）の使用 |
| JP7432716B2 (ja) * | 2019-11-13 | 2024-02-16 | 合肥瀚科邁博生物技術有限公司 | ヒト４－１ｂｂに結合可能な分子及びその応用 |
| CA3177717A1 (en) * | 2020-05-13 | 2021-11-18 | Adagene Ag | Compositions and methods for treating cancer |
| WO2021226883A1 (en) * | 2020-05-13 | 2021-11-18 | Adagene Ag | Compositions and methods for treating cancer submission of sequence listing on ascii text file |
| CA3181677A1 (en) * | 2020-06-23 | 2021-12-30 | Guizhong Liu | Combination therapy comprising anti-cd137 antibodies |
| GB202210957D0 (en) * | 2022-07-27 | 2022-09-07 | Alligator Bioscience Ab | Novel dosages |
| GB202210965D0 (en) * | 2022-07-27 | 2022-09-07 | Alligator Bioscience Ab | Novel dosages |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030118588A1 (en) * | 1999-05-22 | 2003-06-26 | Linda Diehl | Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40 |
| US20070253961A1 (en) * | 2004-06-09 | 2007-11-01 | Ulsan Industrial Education Foundation | Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis |
| ES2720160T3 (es) * | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| CN1294146C (zh) * | 2005-10-17 | 2007-01-10 | 山东大学 | 与t细胞表面共刺激分子cd137结合的多肽及其应用 |
| ES2336873B1 (es) * | 2007-11-07 | 2011-01-24 | Proyecto De Biomedicina Cima, S.L. | Composicion farmaceutica para el tratamiento de cancer. |
| SG11201604965RA (en) * | 2013-12-20 | 2016-07-28 | Univ Singapore | Differentiation therapy with cd137 ligand agonists |
| TW201632559A (zh) * | 2015-02-22 | 2016-09-16 | 索倫多醫療公司 | 結合ｃｄ１３７之抗體治療劑 |
| JP6845846B6 (ja) * | 2015-09-22 | 2021-04-21 | ディンフー バイオターゲット カンパニー リミテッド | 抗ヒトｃｄ１３７の完全ヒト抗体及びその用途 |
| ES2986067T3 (es) * | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
-
2017
- 2017-12-01 WO PCT/CN2017/114247 patent/WO2019104716A1/en not_active Ceased
-
2018
- 2018-11-30 CN CN201880073534.3A patent/CN111344014A/zh active Pending
- 2018-11-30 CA CA3079479A patent/CA3079479A1/en active Pending
- 2018-11-30 AU AU2018377751A patent/AU2018377751A1/en not_active Abandoned
- 2018-11-30 SG SG11202004939SA patent/SG11202004939SA/en unknown
- 2018-11-30 EP EP18883687.8A patent/EP3717010A4/en not_active Withdrawn
- 2018-11-30 JP JP2020528402A patent/JP2021507877A/ja active Pending
- 2018-11-30 WO PCT/CN2018/118631 patent/WO2019105468A1/en not_active Ceased
- 2018-11-30 US US16/768,500 patent/US20200377608A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021507877A5 (enExample) | ||
| JP7438939B2 (ja) | Ｃｄ１３７を標的とする抗体とその利用方法 | |
| JP2020105204A (ja) | Ｐｄ−１／ｐｄ−ｌ１シグナル伝達を破壊することによる癌免疫療法 | |
| JP7809062B2 (ja) | 療法において使用するための抗体 | |
| JP2019519492A5 (enExample) | ||
| RS67652B1 (sr) | Postupak lečenja kancera primenom inhibitora imunološke kontrolne tačke; antitelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1) | |
| CA3015938A1 (en) | Anti-lag-3 antibodies | |
| KR20170102167A (ko) | 항-pd-l1 항체 | |
| RU2015129551A (ru) | Антитела к в7-н4 человека и их применение | |
| CN112703012A (zh) | 治疗癌症的方法 | |
| JP2014531409A5 (enExample) | ||
| JP7459058B2 (ja) | Ｃｄ１３７／ｈｅｒ２二重特異性物質とｐｄ－１系阻害物質とを含む併用療法およびその使用法 | |
| US12570757B2 (en) | Antibodies against the poliovirus receptor (PVR) and uses thereof | |
| JPWO2021011885A5 (enExample) | ||
| US20250092127A1 (en) | IL-4/IL-13 Pathway Inhibitors for Enhanced Efficacy in Treating Cancer | |
| JP2019517504A (ja) | 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ−１遮断 | |
| JP2020522512A5 (enExample) | ||
| CN118871467A (zh) | 抗pd-l2抗体 | |
| RU2009131838A (ru) | Антитела, модифицирующие раковые заболевания | |
| JP2016013104A (ja) | 抗イヌｃｄ２０モノクローナル抗体又は抗体フラグメント、キット、診断方法、治療用組成物、治療方法、核酸、ベクター、キメラ抗原受容体及びｔ細胞 | |
| KR20250012612A (ko) | 고형 종양을 치료하는 방법 | |
| WO2023227115A1 (en) | A method of treating solid tumor | |
| RU2836467C2 (ru) | Ингибиторы пути il-4/il-13 для повышенной эффективности при лечении злокачественных новообразований | |
| KR20250140106A (ko) | 인간 항-pd-l2 항체 및 이의 용도 | |
| KR20240153603A (ko) | Ctla-4 및 pd-1 이중특이적 항체를 사용한 치료 방법 |